Efficacy and safety of infliximab and adalimumab in Crohn's disease: A single centre study

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 12, 2012, Pages 1397-1407

  Zorzi, F ^a   Zuzzi, S ^a   Onali, S ^a   Calabrese, E ^a   Condino, G ^a   Petruzziello, C ^a   Ascolani, M ^a   Pallone, F ^a   Biancone, L ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; BUDESONIDE; INFLIXIMAB; MERCAPTOPURINE; PREDNISOLONE; STEROID;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HERPES ZOSTER; HUMAN; INFUSION RELATED REACTION; LONGITUDINAL STUDY; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; RISK ASSESSMENT; SMOKING CESSATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX DYSPLASIA;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84861198222     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05100.x     Document Type: Article

References (37)

1. Kaser A, Zeissing S, Blumberg RS,. Inflammatory Bowel disease. Annu Rev Immunol 2010; 28: 573-621.
2. Van Deventer SJ,. Tumour necrosis factor and Crohn's disease. Gut 1997; 40: 443-8. (Pubitemid 27204920)
3. Breese EJ, Michie CA, Nicholls SW, et al,. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106: 1455-66. (Pubitemid 24163114)
4. Schreiber S, Nikolaus S, Hampe J, et al,. Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease. Lancet 1999; 353: 459-61. (Pubitemid 29067338)
5. Targan SR, Hanauer SB, Van Denever SJ, et al,. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
6. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9. (Pubitemid 34621118)
7. Sands BE, Anderson FH, Bernstein CN, et al,. Infliximab maintenance therapy for fistulizing Crohn's Disease. N Engl J Med 2004; 350: 876-85. (Pubitemid 38252535)
8. Present DH, Rutgeerts P, Targan S, et al,. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405. (Pubitemid 29205403)
9. Rutgeerts P, Diamond RH, Bala M, et al,. Scheduled maintenance treatment with Infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63: 433-17.
10. Dignass A, Van Assche G, Lindsay JO, et al,. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28-62.
11. Baert F, Noman M, Vermeire S, et al,. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8. (Pubitemid 36204954)
12. Hanauer SB, Sandborn WJ, Rutgeerts P, et al,. Human anti tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-33.
13. Sandborn WJ, Hanauer SB, Rutgeerts P, et al,. Adalimumab for maintenance treatment of Crohn's disease results of the CLASSIC II trial. Gut 2007; 56: 1232-9. (Pubitemid 47300424)
14. Colombel JF, Sandborn WJ, Rutgeerts P, et al,. Adalimumab is effective in maintenance of clinical response and remission in patients with active Crohn's disease: results of the CHARM trial. Gastroenterology 2007; 132: 52-65. (Pubitemid 46108762)
15. Rutgeerts P, Van Assche G, Sandborn WJ, et al,. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012 [Epub ahead of print].
16. Sandborn WJ, Rutgeerts P, Enns R, et al,. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-38. (Pubitemid 351650483)
17. Hinojosa J, Gomollõn F, García S, et al,. Efficacy and safety of short-therm adalimumab treatment in patients with active Crohn's disease who loss response or showed intolerance to infliximab: a prospective, open label, multicenter trial. Aliment Pharmacol Ther 2007; 25: 409-18. (Pubitemid 46184454)
18. Van Assche G, Dignass A, Panes J, et al,. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010; 4: 7-27.
19. Orlando A, Armuzzi A, Papi C, et al,. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) clinical practice guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis 2011; 43: 1-20.
20. Cottone M, Rosselli M, Orlando A, et al,. Smoking habits and recurrence in Crohn's disease. Gastroenterology 1994; 106: 643-8. (Pubitemid 24064330)
21. Silverberg MS, Satsangi J, Ahmad T, et al,. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19: 5-36.
22. Best WR, Becktel JM, Singleton JW, et al,. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
23. Clark M, Colombel JF, Feagan BC, et al,. American Gastroenterological Association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007; 133: 312-39. (Pubitemid 47031141)
24. Schwartz DA, Pemberton JH, Sandborn WJ,. Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intern Med 2001; 135: 906-18. (Pubitemid 33070686)
25. Guyatt G, Mitchell A, Irvine EJ, et al,. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96: 804-10. (Pubitemid 19057603)
26. Schnitzler F, Fidder H, Ferrante M, et al,. Long-term outcome of treatment with Infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
27. Ha C, Ullman TA, Siegel CA, et al,. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol 2012 [Epub ahead of print].
28. Trinder MW, Lawrance IC,. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. J Gastroenterol Hepatol 2009; 24: 1252-7.
29. Cohen RD, Kisiel JB, Hanauer SB,. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 1999; 94: A2642.
30. Farrell RJ, Shah SA, Lodhavia PJ, et al,. Clinical experience with Infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000; 95: 3490-7.
31. Swoger JM, Loftus EV, Tremaine WJ, et al,. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis 2010; 16: 1912-21.
32. Schreiber S, Khaliq-Kareemi M, Lauwrance I, et al,. Mainteinance therapy with certulizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-50. (Pubitemid 47080388)
33. Kugathasan S, Saubermann L, Smith L, et al,. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 2007; 56: 1696-705. (Pubitemid 350206296)
34. Louis E, Belaiche J, Reenaers C,. Anti-Tumor Necrosis factor nonresponders in Crohn's disease: therapeutic strategies. Dig Dis 2009; 27: 351-7.
35. Vermeire S, Louis E, Carbonez A, et al,. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002; 97: 2357-63.
36. Sprakes MB, Ford AC, Warren L, et al,. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. J Crohns Colitis 2012; 6: 143-53.
37. Cheifetz A, Smedley M, Martin S, et al,. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315-24. (Pubitemid 36741529)